Entrectinib, an oral pan-TRK, ROS1 and ALK kinase inhibitor, was tested in 54 adult, NTRK rearranged cancer patients, yielding an ORR of 57% and showing a safety profile comparable with larotrectinib [76]. The gene discussed is NTRK1; the disease is cancer.